Therapeutic | Denosumab |
Target | TNFSF11 |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Abgenix XenoMouse |
INN Year Proposed | 2005 |
INN Year Recommended | 2006 |
Companies Involved | Amgen, Daiichi Sankyo Company, European Thoracic Oncology Platform, GlaxoSmithKline, Jules Bordet Institute, Melbourne Health, University Health Network |
Conditions Approved | Bone cancer, Bone disorders, Bone metastases, Corticosteroid-induced osteoporosis, Male osteoporosis, Malignant hypercalcaemia, Osteoporosis, Postmenopausal osteoporosis, Rheumatoid arthritis |
Conditions Active | Breast cancer, Non-small cell lung cancer, Osteogenesis imperfecta, Malignant melanoma |
Conditions Discontinued | Multiple myeloma |
Notes |